TY - JOUR
T1 - Safety, dosimetry and tumor detection ability of 68Ga-NOTA-AE105 - a novel radioligand for uPAR PET imaging
T2 - first-in-humans study
AU - Skovgaard, Dorthe
AU - Persson, Morten
AU - Brandt-Larsen, Malene
AU - Christensen, Camilla
AU - Madsen, Jacob
AU - Klausen, Thomas Levin
AU - Holm, Soeren
AU - Andersen, Flemming Littrup
AU - Loft, Annika
AU - Berthelsen, Anne Kiil
AU - Pappot, Helle
AU - Brasso, Klaus
AU - Kroman, Niels
AU - Hoejgaard, Liselotte
AU - Kjaer, Andreas
N1 - Copyright © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PY - 2017
Y1 - 2017
N2 - INTRODUCTION: Overexpression of urokinase-type plasminogen activator receptors (uPAR) represents an established biomarker for aggressiveness in most common malignant diseases, including breast (BC), prostate (PC) and urinary bladder cancer (UBC) and is therefore an important target for new cancer therapeutic and diagnostic strategies. In the study, uPAR Positron Emission Tomography (PET) imaging using a (68)Ga-labelled version of the uPAR targeting peptide (AE105) was investigated in a group of patients with BC, PC and UBC. The aim of this first-in-humans, Phase I, clinical trial was to investigate safety and biodistribution in normal tissues and uptake in tumor lesions.METHODS: Ten patients (6 PC, 2 BC and 2 UBC) received a single intravenous dose of (68)Ga-NOTA-AE105 (154 + 59 MBq; range 48-208 MBq). The biodistribution and radiation dosimetry were assessed by serial PET/CT scans (10 minutes, 1 and 2 hours p.i.). Safety assessment included measurements of vital signs with regular intervals during the imaging sessions and laboratory blood screening tests performed before and after injection. In a subgroup of patients, the in vivo stability of (68)Ga-NOTA-AE105 was determined in collected blood and urine. PET images were visually analyzed for visible tumor uptake of (68)Ga-NOTA-AE105 and Standardized Uptake Values (SUVs) were obtained from tumor lesions by manually drawing volumes of interest (VOIs) in the malignant tissue.RESULTS: No adverse events or clinically detectable pharmacologic effects were found. The radioligand exhibited good in vivo stability and fast clearance from tissue compartments primarily by renal excretion. The effective dose was 0.015 mSv/MBq leading to a radiation burden of 3 mSv when using the clinical target dose of 200 MBq. In addition, radioligand accumulation was seen in primary tumor lesions as well as in metastases.CONCLUSION: This first-in-humans, Phase 1 clinical trial demonstrates the safe use and clinical potential of (68)Ga-NOTA-AE105 as a new radioligand for uPAR PET imaging in cancer patients.
AB - INTRODUCTION: Overexpression of urokinase-type plasminogen activator receptors (uPAR) represents an established biomarker for aggressiveness in most common malignant diseases, including breast (BC), prostate (PC) and urinary bladder cancer (UBC) and is therefore an important target for new cancer therapeutic and diagnostic strategies. In the study, uPAR Positron Emission Tomography (PET) imaging using a (68)Ga-labelled version of the uPAR targeting peptide (AE105) was investigated in a group of patients with BC, PC and UBC. The aim of this first-in-humans, Phase I, clinical trial was to investigate safety and biodistribution in normal tissues and uptake in tumor lesions.METHODS: Ten patients (6 PC, 2 BC and 2 UBC) received a single intravenous dose of (68)Ga-NOTA-AE105 (154 + 59 MBq; range 48-208 MBq). The biodistribution and radiation dosimetry were assessed by serial PET/CT scans (10 minutes, 1 and 2 hours p.i.). Safety assessment included measurements of vital signs with regular intervals during the imaging sessions and laboratory blood screening tests performed before and after injection. In a subgroup of patients, the in vivo stability of (68)Ga-NOTA-AE105 was determined in collected blood and urine. PET images were visually analyzed for visible tumor uptake of (68)Ga-NOTA-AE105 and Standardized Uptake Values (SUVs) were obtained from tumor lesions by manually drawing volumes of interest (VOIs) in the malignant tissue.RESULTS: No adverse events or clinically detectable pharmacologic effects were found. The radioligand exhibited good in vivo stability and fast clearance from tissue compartments primarily by renal excretion. The effective dose was 0.015 mSv/MBq leading to a radiation burden of 3 mSv when using the clinical target dose of 200 MBq. In addition, radioligand accumulation was seen in primary tumor lesions as well as in metastases.CONCLUSION: This first-in-humans, Phase 1 clinical trial demonstrates the safe use and clinical potential of (68)Ga-NOTA-AE105 as a new radioligand for uPAR PET imaging in cancer patients.
U2 - 10.2967/jnumed.116.178970
DO - 10.2967/jnumed.116.178970
M3 - Journal article
C2 - 27609788
SN - 0161-5505
VL - 58
SP - 379
EP - 386
JO - Journal of nuclear medicine : official publication, Society of Nuclear Medicine
JF - Journal of nuclear medicine : official publication, Society of Nuclear Medicine
IS - 3
ER -